An online, cloud-based
Transfer-solution System
for your clinical trials
IMITS transfer-solution makes it simple to manage clinical trials in the field of medical imaging. A powerful and completely configurable platform allows for easy management of multi-center trials in one innovative, unified cloud architecture.
Our Transfer Solution is cloud-based convenient secure
Our Solution
Fully Cloud-based solution
As the IMITS Transfer® is web-based, no special configurations or alterations in hospital firewalls are required. The system works both for Windows and Mac computers.
Anonymized transfer of images
IMITS Transfer® uses an e-CRF system enabling a secure and professional work process. The medical images are anonymized during upload and transfer.
Role-Based Access
Different user levels are designed in the system, to address the role of the user. From assigned full access for administrators to part of access for specific users.
High Availability and Uptime
High operational performance of transfer-solution to ensure continuous availability.
Users and Trials
IMITS is used by ImaCor AB, a company that serves as a CMR Core laboratory in different clinical multi-center trials since 2010. These trials are centered on quantitative assessment of the effect of new therapies in acute myocardial infarction.
The services performed by ImaCor include site training, reviewing of CMR data for quality control and quantification of the CMR outcome variables (infarct size, myocardium at risk, myocardial salvage, myocardial salvage index, microvascular obstruction and left ventricular function).
Clinical trials where IMITS is used:
CHILL-MI trial
Uppsala Clinical Research Center, Sweden
J Am Coll Cardiol. 2014 May 13;63(18):1857-65
Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction.
MITOCARE trial
European Commission and Trophos SA, France
Eur Heart J. 2015 Jan 7;36(2):112-9. doi: 10.1093/eurheartj/ehu331. Epub 2014 Sep 1.
Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results
Link: http://eurheartj.oxfordjournals.org/content/early/2014/08/25/eurheartj.ehu331.full-text.pdf
COOL-AMI EU Pilot
ZOLL Circulation, Inc, USA
EuroIntervention. 2017 May 17. pii: EIJ-D-17-00279. doi: 10.4244/EIJ-D-17-00279. [Epub ahead of print]
The COOL-AMI EU Pilot trial: A multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction
About the Company
IMITS (International Medical Image Transfer System) has been developed by Imacor AB, a company formed by members of the Cardiac MR group at Lund University, Sweden.
Imacor was founded in order to meet the markets´ increased demand for unbiased evaluation of medical images for medical and scientific purposes. As a result, IMITS Transfer software was developed and its features are continuously quality improved through the ongoing use in clinical trials. Imacor personnel using IMITS all have a thorough scientific track record.
ImaCor AB provides core lab services to clients such as public and private organizations engaging in medical or scientific activities. Through IMITS the acquired CMR data will be transferred electronically to the core laboratory.
The image repository database has a web-interface to allow users to monitor upload progress, for quality review, or monitor patient enrollment. As the IMITS Transfer software utilizes direct access to the HTTP port for image transfer, no special configurations or alterations in hospital firewalls are required. For more details, see: “Solution”.
Get in Touch With Us
Contact Us
Get in Touch
Do you have any questions or comments about our platform? Feel free to contact us!